Today, a Director at Becton Dickinson (BDX), Catherine Burzik, bought shares of BDX for $82.57K.
Following this transaction Catherine Burzik’s holding in the company was increased by 3.74% to a total of $2.34 million. In addition to Catherine Burzik, one other BDX executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
BDX’s market cap is $63.12B and the company has a P/E ratio of 69.44. Currently, Becton Dickinson has an average volume of 341.3K.
Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $268.00, reflecting a 14.5% upside. Seven different firms, including Argus Research and Raymond James, currently also have a Buy rating on the stock. Starting in May 2019, BDX received 5 Buy ratings in a row.
In the last 30 days, insiders have sold $3.78M worth of BDX shares and purchased $82.57K worth of BDX shares. The insider sentiment on Becton Dickinson has been negative according to 70 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
